F10 and atrial fibrillation: The same primary outcome will be tested in the ENTRUST AF-PCI trial (clinicaltrials.gov NCT02866175), which will randomize patients with AF undergoing PCI, to evaluate a treatment regimen based on the other direct factor Xa-inhibitor edoxaban once daily plus P2Y12 receptor antagonist (for 12 months) against warfarin and a P2Y12 receptor antagonist (for 12 months) plus aspirin (for 30 days to 12 months guided by clinical presentation, CHA2DS2-VASc and HASBLED scores) (Vranckx et al., 2017) (Table 1).